Abattis Selects Ingredient Identity as Global Regulatory Management Partner

Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (ATTBF)(CSE:ATT), a specialty biotechnology company with capabilities through its wholly-owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal... more →
Posted in: Press

GHG Flying As Abattis Is Building An Empire

Speaking of big names, Tweed ( TSX:V.TWD , Stock Forum ) has brought in a bought financing deal worth potentially $19.5 million for ‘facility expansions and general corporate purposes’, at $3.20 per share. The company, which is taking orders, backfilling with old-system-bought product, and generally dominating the scene... more →
Posted in: News